Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)

NCT04758975 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG: Venetoclax
DRUG: Rituximab
DRUG: Ibrutinib

Sponsor

Paolo Ghia